DBV Technologies (NASDAQ:DBVT) Shares Up 4.9% - Here's What Happened

Key Points

• DBV Technologies shares rose 4.9% to $12.13 in Monday trading, with approximately 281,502 shares changing hands.
• Analyst sentiment remains mixed but leans positive: five analysts rate the stock Buy, one Hold, and one Sell, producing a “Moderate Buy” consensus and a $48.50 average price target.
• Institutional investors own 71.74% of the company, with several firms recently increasing stakes or initiating positions in DBV Technologies.

DBV Technologies S.A. (NASDAQ:DBVT - Get Free Report) shares were up 4.9% during trading on Monday. The stock traded as high as $12.00 and last traded at $12.13. Approximately 281,502 shares were traded during trading, a decline of 6% from the average daily volume of 300,963 shares. The stock had previously closed at $11.56.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. HC Wainwright reiterated a "buy" rating on shares of DBV Technologies in a research note on Tuesday, June 30th. Citizens Jmp lifted their price target on shares of DBV Technologies from $47.00 to $55.00 and gave the stock a "market outperform" rating in a research note on Tuesday, June 30th. Wall Street Zen downgraded shares of DBV Technologies from a "hold" rating to a "sell" rating in a research report on Saturday, July 4th. Weiss Ratings cut shares of DBV Technologies from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Friday, July 17th. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of DBV Technologies in a report on Thursday, September 10th. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $48.50.

DBV Technologies Price Performance

The firm has a market cap of $734.06 million, a price-to-earnings ratio of -3.36 and a beta of -0.95. The stock has a 50-day moving average price of $13.51 and a 200 day moving average price of $16.84.

Institutional Trading of DBV Technologies

Several institutional investors and hedge funds have recently bought and sold shares of the business. Royal Bank of Canada increased its stake in DBV Technologies by 167.1% in the first quarter. Royal Bank of Canada now owns 4,680 shares of the company's stock valued at $98,000 after purchasing an additional 2,928 shares during the period. Personal CFO Solutions LLC acquired a new position in DBV Technologies in the 1st quarter valued at about $264,000. Cetera Investment Advisers raised its stake in DBV Technologies by 93.4% during the 1st quarter. Cetera Investment Advisers now owns 25,358 shares of the company's stock valued at $530,000 after acquiring an additional 12,243 shares during the last quarter. AdvisorShares Investments LLC acquired a new stake in DBV Technologies during the 1st quarter worth approximately $1,052,000. Finally, Polymer Capital Management HK LTD acquired a new stake in DBV Technologies during the 4th quarter worth approximately $1,236,000. Hedge funds and other institutional investors own 71.74% of the company's stock.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company focused on developing treatments for food allergies and other immune-mediated conditions. The company's lead technology, Viaskin, is designed to deliver targeted immunotherapy through the skin without requiring an injection. Its approach is intended to expose the immune system to controlled amounts of an allergen while limiting systemic exposure.

DBV Technologies' primary product candidate is Viaskin Peanut, an investigational patch intended to treat peanut allergy, particularly in children.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.